Q2 2026 AtriCure Inc Earnings Call Transcript
Key Points
- AtriCure Inc (ATRC) reported a solid second-quarter revenue of $154 million, marking a 13% growth year-over-year.
- The company achieved over $27 million in adjusted EBITDA and $9 million in net income, indicating strong profitability improvements.
- The BoxX-NoAF clinical study has surpassed the 50% enrollment mark, with over 500 patients enrolled, ahead of schedule.
- The pain management franchise experienced a 27% worldwide growth, driven by the adoption of cryoSPHERE MAX.
- AtriCure Inc (ATRC) raised its full-year adjusted EBITDA outlook to approximately $85 million to $89 million, reflecting confidence in continued financial performance.
- The minimally invasive ablation business remains under pressure due to market focus on PFA catheters.
- International revenue growth was slower, with a 9.6% increase on a reported basis and 7.1% on a constant-currency basis.
- The UK market continues to face challenges, with sequentially flat performance due to reimbursement issues.
- The company anticipates ongoing pressure within MIS ablation and certain international markets.
- There is a potential risk of competition in the appendage management market, with new entrants possibly impacting market share.
Good afternoon, and welcome to AtriCure's second-quarter 2026 earnings conference call. This call is being recorded for replay purposes. (Operator Instructions)
I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments. You may begin.
Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call 513-644-4484 to have one emailed to you.
Before we begin today, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings.
These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure's franchises and growth initiatives, future product approvals and clearances,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
